Sodium oxybate in the treatment of alcohol withdrawal syndrome: a randomized double-blind comparative study versus oxazepam. The GATE 1 trial

Giovanni Addolorato; Fabio Caputo; Katrin Skala; Henriette Walter; Otto Lesch

doi:10.1007/s40263-014-0183-1

Sodium oxybate in the treatment of alcohol withdrawal syndrome: a randomized double-blind comparative study versus oxazepam. The GATE 1 trial

Giovanni Addolorato, Fabio Caputo, Katrin Skala, Henriette Walter, Otto Lesch

Risultato della ricerca: Contributo in rivista › Articolo in rivista

17 Citazioni (Scopus)

Abstract

Benzodiazepines (BDZs) are the gold standard in the treatment of alcohol withdrawal syndrome (AWS). Sodium oxybate (SMO) has been tested as a treatment for AWS with encouraging results. The aim of this phase IV, multicenter, randomized, double-blind, double-dummy study was to evaluate the efficacy of SMO in comparison with oxazepam in the treatment of uncomplicated AWS.

Lingua originale	English
pagine (da-a)	743-752
Numero di pagine	10
Rivista	CNS Drugs
Volume	28
DOI	https://doi.org/10.1007/s40263-014-0183-1
Stato di pubblicazione	Pubblicato - 2014

Keywords

alcohol withdrawal syndrome
sodium oxybate

Accesso al documento

10.1007/s40263-014-0183-1

Altri file e collegamenti

Link a IRIS PubliCatt

Fingerprint Entra nei temi di ricerca di 'Sodium oxybate in the treatment of alcohol withdrawal syndrome: a randomized double-blind comparative study versus oxazepam. The GATE 1 trial'. Insieme formano una fingerprint unica.

Cita questo

@article{18a7a90d30f046b496964d953e3e02d2,

title = "Sodium oxybate in the treatment of alcohol withdrawal syndrome: a randomized double-blind comparative study versus oxazepam. The GATE 1 trial",

abstract = "Benzodiazepines (BDZs) are the gold standard in the treatment of alcohol withdrawal syndrome (AWS). Sodium oxybate (SMO) has been tested as a treatment for AWS with encouraging results. The aim of this phase IV, multicenter, randomized, double-blind, double-dummy study was to evaluate the efficacy of SMO in comparison with oxazepam in the treatment of uncomplicated AWS.",

keywords = "alcohol withdrawal syndrome, sodium oxybate, alcohol withdrawal syndrome, sodium oxybate",

author = "Giovanni Addolorato and Fabio Caputo and Katrin Skala and Henriette Walter and Otto Lesch",

year = "2014",

doi = "10.1007/s40263-014-0183-1",

language = "English",

volume = "28",

pages = "743--752",

journal = "CNS Drugs",

issn = "1172-7047",

publisher = "Adis International Limited:Private Bag 65901, Mairangi Bay, Auckland 1311 New Zealand:011 64 9 4770741, EMAIL: subs@adis.com, david.herrick@adis.co.nz, INTERNET: http://www.adis.com, Fax: 011 64 9 4770766",

}

TY - JOUR

T1 - Sodium oxybate in the treatment of alcohol withdrawal syndrome: a randomized double-blind comparative study versus oxazepam. The GATE 1 trial

AU - Addolorato, Giovanni

AU - Caputo, Fabio

AU - Skala, Katrin

AU - Walter, Henriette

AU - Lesch, Otto

PY - 2014

Y1 - 2014

N2 - Benzodiazepines (BDZs) are the gold standard in the treatment of alcohol withdrawal syndrome (AWS). Sodium oxybate (SMO) has been tested as a treatment for AWS with encouraging results. The aim of this phase IV, multicenter, randomized, double-blind, double-dummy study was to evaluate the efficacy of SMO in comparison with oxazepam in the treatment of uncomplicated AWS.

AB - Benzodiazepines (BDZs) are the gold standard in the treatment of alcohol withdrawal syndrome (AWS). Sodium oxybate (SMO) has been tested as a treatment for AWS with encouraging results. The aim of this phase IV, multicenter, randomized, double-blind, double-dummy study was to evaluate the efficacy of SMO in comparison with oxazepam in the treatment of uncomplicated AWS.

KW - alcohol withdrawal syndrome

KW - sodium oxybate

KW - alcohol withdrawal syndrome

KW - sodium oxybate

UR - http://hdl.handle.net/10807/60505

U2 - 10.1007/s40263-014-0183-1

DO - 10.1007/s40263-014-0183-1

M3 - Article

VL - 28

SP - 743

EP - 752

JO - CNS Drugs

JF - CNS Drugs

SN - 1172-7047

ER -